The latest trading session saw CVS Health (CVS) ending at $45.78, denoting a -0.09% adjustment from its last day's close. This change was narrower than the S&P 500's 1.11% loss on the day. Meanwhile, ...

Shares of CVS Health Corp. CVS slid 0.09% to $45.78 Tuesday, on what proved to be an all-around poor trading session for the ...

Washington State’s program is the first, but other states are expected to try allowing pharmacists to prescribe the pills to ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Truist analyst David MacDonald lowered the firm’s price target on CVS Health (CVS) to $60 from $67 and keeps a Buy rating on ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets.

Zydus Lifesciences announces CVS Caremark agreement and FDA priority review for diabetes and Menkes disease treatments.

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS ...